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ABSTRACT 
Background: There is growing interest on costs of clinical trials; critical topic for 
business decision making; therefore, the aim of this work is to identify how a successful 
Brazilian case measures its economic performance even with restriction regarding its 
accounting data.  
Methods: Single case qualitative method.  Interviews with four people of different 
hierarchical levels and the analysis of the 2005 balance sheet, payrolls and payment 
slips were carried out. 
Results: Besides indicating how the clinical research unit of the case measures its 
results, a diagram of how other units and organizations could follow such procedure to 
carry out their own performance measurement was pointed out as well. 
Conclusion: The use of contribution margin and break-even point for the performance 
calculation benefited the managerial decision-making of the unit studied, serving as 
basis for its own strategy and use of its idleness. This is a reference model for decision-
making of managers in other research units. 
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RESUMO 
Background: Há um interesse crescente sobre custos em ensaios clínicos; tópico 
crítico para a tomada de decisão empresarial, por isso o objetivo do presente trabalho 
é identificar como um caso de sucesso brasileiro mensura seu desempenho 
econômico mesmo com restrições nas suas informações contábeis.  
Métodos: Método qualitativo de estudo de caso único. Realizou-se entrevistas com 
quatro indivíduos de diferentes níveis hierárquicos e análise de balancetes, folhas de 
pagamentos e notas de pagamento do ano de 2015. 
Resultados: Além de apontar como a unidade de pesquisa clínica do caso mensura 
seu resultado foi apontado um diagrama de como outras unidades e organizações 
poderiam seguir tal procedimento para realizar uma mensuração de seu próprio 
desempenho. 
Conclusão: A utilização de margem de contribuição e ponto de equilíbrio para cálculo 
do desempenho favoreceu a tomada de decisão gerencial da unidade estudada, 
servindo como base para estratégia da mesma e uso de sua ociosidade. Este é um 
modelo de referência para tomada de decisão de gestores em outras unidades de 
pesquisa. 
 
Palavras-chave: Performance econômica; Resultado econômico; Atividade sem fins 
lucrativos. 
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The costs of clinical trials worldwide presented growth and generated great 
concern in the last decade1, increasing the discussion and interest of studies on the 
subject2,3,4,5. Such costs used to involve the use of resources associated to the delivery 
of a very specific service6 which makes its measurement difficult.  
The suitable measurement of costs, return and, consequently, economic 
performance, is essential for any business7,8. As the organization reaches these 
results, the proportion of its success becomes clear9; therefore, it is expected that the 
intended volume of the right product for a certain existing need is placed in the market 
by a company10 being financially viable11.  
Identifying how much to produce, how much to charge or even whether a service 
may or may not be delivered, is key investment and coordination decisions for a 
company12. Being the Clinical Trials Units (CTU) specialized research entities which 
can help in the design and central coordination of studies13, it is understood that they 
also have to measure their performance in order to make the decisions described.  
 At the limit, what is always sought is the number of services to be delivered so 
that the CTU have a result that does not imply loss14. From this moment on, called 
break-even point, it is understood that there is good performance and positive 
results15,16. 
Thus, the aim of this work is to understand how a clinical trials unit measures its 
performance in order to make managerial decisions, even having incomplete 
information on its costs.  Generating a framework which may serve as a reference 
model for several other clinical trials units, as well as precedents for the improvement 
in performance assessment in other activities and non-profit organizations. 
 
METHODS 
Questions such as “how” and “why”are more explanatory and are used to 
leading to the use of case studies, historical researches or experiments; nevertheless, 
case study is the preferred one in examining the contemporary events and when the 
researcher has little or no control over such events17. While lab experiments isolate 
the phenomena from their contexts, case studies emphasize the rich and actual 
context in which the phenomena take place18. 
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In fact, case studies can be used to carry out several objectives, such as:  
provide a description, test theory, or generate theory19. With this work, it was sought 
to not only describe the mechanisms by which the CTU measures its performance and 
makes its managerial decisions, but also to suggest a diagram of “boxes and arrows”18 
that can be used by other clinical trials units.  
 
Collection Methods 
Since the data triangulation enabled by multiple collection methods provides 
stronger evidence of the constructs within the research, helping to deal with the 
problems of validity and reliability17, this study used three methods:  in-depth interviews 
with the managers and financial officers, document analysis and observation.  
 The interviews were held from February to September/2017, with 4 people of 
different hierarchical levels of the organization: manager in charge of the CTU, 
coordinator of clinical studies, hospital financial officer where the CTU is linked to and 
the financial director of the foundation responsible for the CTU.  
 The documents analyzed were: 2015 balance consolidated by the foundation in 
charge of the CTU, 2015 balance and payrolls consolidated by the hospital referring to 
the CTU data, payment invoices regarding the protocols used in the case assessed.   
 The data used by the CTU, and consecutively in this research, refer to 2015, as 
it can be observed above.  The need of complete data on the year led to the use of 
this year which was the most recent one and whose balance sheet was complete and 
closed. The study was not harmed, since there were no great changes in the values 
used, due to an internal policy of freezing the expenditure by the hospital.   
 
Table 1 – Case Study Protocol 
Question of the Study How does a trials unit measure its performance in 
order to make managerial decisions? 
Analysis Unit Mechanism of performance measurement.   
Time Limits From February to September/2017. 
Venue Brazilian Clinical Trials Unit. 
Construct Validity Theoretical-practical contraposition, based on the 
theme state-of-the-art.  
 Gestão em Saúde 
 
Revista Inova Saúde, Criciúma, vol. 11, n. 1, Fevereiro, 2021. ISSN 2317-2460 
 
147 
Internal Validity Use of 3 evidence sources: interviews, observation 
and documents.  
Study Fundamental Questions - What does the CTU understand by performance?  
- What data do they have for calculating 
performance? 
- What do they do in order to ascertain whether this 
performance is being reached?  
- How is this performance used in managerial 




Linked to a public university hospital, the unit was founded in 2005 and it has a 
30-people staff who is allocated in a facility containing file rooms, meeting and training 
rooms, dedicated and air-conditioned lab, pharmacy and nursing. The CTU works with 
the main pharmaceutical companies of the world. 
When an agreement with a client is signed, a research protocol (each protocol 
regards a drug to be tested and it has the defined number of visits each trial attendee  
must carry out in the trials unit) begins. The number of exams per visit, the number of 
visits per attendee and the number of attendees in the protocol are defined by the 
agreement.  The amount to be earned by the CTU per each visit carried out, based on 
the type and number of exams to be performed in the visit, is also defined in the 
agreement. 
Two kinds of protocols can be performed:  Academic, developed by research 
professors aiming to increase knowledge in a drug; and that of the pharmaceutical 
industry, aiming to launch a new product in the market. The company follows, and 
pays, each visit carried out by a research attendee. Thus, the control by the CTU for 
this kind of protocol is performed by visit. Academic protocols are paid by the total of 
exams carried out, leading to a control per number of exams. The managers used one 
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Measurement of the unit’s fixed costs  
Fixed costs are those necessary for the physical functioning of the organization.  
It is everything that does not change values in case of increase or decrease of 
production and sales volumes, which does not depend on the activity level20. As the 
production volume increases, the unit fixed costs decrease. The higher the number is, 
the greater the gains of economies of scale and the lower the unit fixed costs21. 
 It is easy to notice that regardless the existence of the CTU, the hospital costs, 
its sponsor, would still exist, and hence constitutes a sunk cost: “Sunk cost is a cost 
that has already been incurred and cannot be avoided regardless of what a manager 
decides to do” 16. 
Following the concept presented, it was ruled out the fact that costs would not 
be changed by the absence of CTU, therefore, just the costs associated with its 
existence, that is, the relevant cost for decision-making, were kept (table 2).  
 
Table 2 – Fixed Costs relevant for decision-making  





















22,859 31,386 87,646 46,824 188,714 
CONSUMPTION 19,447 25,292 49,679 10,193 104,612 
OTHER COSTS 23,707 8,519 12,466 5,176 49,868 








 It is seen that the CTU existence resulted, in 2015, in a R$ 1,872,645 
incremental cost to the hospital. As comparative measure, it is noticed that such costs 
are below the average found in clinical trials units in the United Kingdom, which in 2014 
was about  £769,6375, equivalent to R$ 3,185,527.54 according to the quotation value 
on December 31, 201422. 
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Revenues and contribution margin of the protocols  
 
 The manager of the trials unit, to measure its performance, selected an industry 
protocol regarded as recurrent profile as a basis. This protocol had its contract signed 
in 2014 and it terminated in 2017, with a 12-month active visit implementation period. 
 The protocol pointed a total of 13 visits carried out during its implementation, 
with administrative surcharge of 15% of the amount defined for the visit (table 6).  At 
first, each visit included 10 attendees.  During each visit, it is necessary that the 
attendee complies with the health restrictions the protocol requires for his/her 
continuity, therefore, 6 attendees reached the last level of visits.  In all, 94 
appointments were carried out, and on average, there were 7.23 volunteers per 
appointment.  
 Cross-checking the amount received per visit with their recurrence, a total 
income of R$ 153,640.00 due to this protocol was ascertained.  The amount was 
confirmed by cross-checking the data of invoices issued and the payments received in 
check account - stage carried out with the monitoring of the coordinator in charge of 
the protocol.    
 When the variable cost component of the analysis of a product or service is 
withdrawn, the Contribution Margin per Unit, difference between the sales price and 
the variable cost of each product, is obtained23.  
 Based on the amounts charged to the industry and the amounts of variable cost 
- stipulated via the price chart of the Sistema Único de Saúde (SUS) – it is verified that 
the protocol contribution margin is R$124,380.53 (table 3).  
 
Table 3 – Contribution Margin of the industry protocol 
Contribution Margin Value (in R$) 
Revenue (amount charged to the industry) R$ 153,640.00 
Variable Cost ( SUS value) (R$ 29,259.49) 
Protocol Contribution Margin R$ 124,380.53 
Contribution Margin per  Volunteer (7.23 volunteers) R$ 17,203.39 
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 Then, a sample of the academic protocol, also pointed as of recurrent profile, 
was analyzed.  The protocol had its contract signed in 2014 and it terminated in 2017, 
with a 12-month and 15-day active visit implementation period. 
 The protocol pointed a level of 4 visits carried out during its implementation.  
Each visit included 30 attendees, with no decrease during its implementation. In all, 
120 appointments were performed.  
With the calculation of the unit value of each exam cross-checked with the 
number of exams carried out in this protocol, it was possible to ascertain a total income 
of R$129,577.00. The amount was confirmed by cross-checking the data present in 
the proofs of delivery of the promotion agency - stage performed with the monitoring 
of the trials unit manager.  
 For the academic protocol, based on the amounts charged for the exams carried 
out and the amounts of determined variable cost, the R$ 103,091.73 contribution 
margin was pointed (table 4).   
 
Table 4 – Contribution margin of the academic protocol  
Contribution margin Amount (in R$) 
Revenue (amount charged for the exams)  R$ 129,576.50 
Variable cost  (SUS value) (R$ 26,484.80) 
Contribution  margin R$ 103,091.73 
Contribution margin per volunteer (30 volunteers) R$ 3,436.39 




 Break-even point  
According to Garrison et al. (2012), the method of contribution margin has, as 
focus, the idea that each unit sold provides a certain volume of financial contribution 
margin to cover the fixed cost. To identify how many units must be sold in order to 
reach a break-even balance, the total fixed expenditures are divided by the contribution 




 Gestão em Saúde 
 
Revista Inova Saúde, Criciúma, vol. 11, n. 1, Fevereiro, 2021. ISSN 2317-2460 
 
151 
 Thus, it is possible to identify that the break-even point for the CTU assessed, 
when it performs its services to pharmaceutical industry, it is equivalent to 15 protocols 
or 1,415 appointments per year (Table 5).  And if all the protocols implemented were 
academic ones, 18 protocols or 2,179 appointments would be necessary in a year 
(Table 6). 
 
Tabel 5 – Break-even point of the industry protocol  
Break-even point  
Yearly CTU fixed cost (R$) R$ 1,872,645.00 
  
Protocol contribution margin  (R$) R$ 124,380.53 
Contribution margin per Volunteer (7.23 volunteers) R$ 17,203.39 
Contribution margin per Appointment (94 appointments) R$ 1,323,20 
  
Protocol break-even point  15.06 protocols/year 
Volunteer break-even point 108.85 volunteers/year 




Table 6 – Break-even point of the Academic Protocol 
Break-even point   
Yearly CTU fixed cost (R$) R$ 1,872,645.00 
  
Protocol contribution margin (R$) R$ 103,091.73 
Volunteer contribution margin (30 volunteers) R$ 3,436.39 
Appointment contribution margin (120 appointments) R$ 859.10 
  
Protocol break-even point 18.16 protocols/year 
Volunteer break-even point 544.95 volunteers/year 






With the information described, the CTU makes expenditure forecasts and 
capacities for its managerial decision-making in each yearly period.   
Since it carried out 266 appointments for industry protocols in the first quarter 
of 2018 and 359 appointments for the academic ones (table 7), based on the 
calculations presented (tables 4 and 5), the CTU assumes that the contribution margin 
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for such period was R$ 351,971.20 for the industry protocols and R$ 308,416.90 for 
the academic ones. Amounts which were repeated during the other semesters of the 
year, as expected, summed up a R$ 2,641,552.40 total contribution margin to cover 
fixed costs.  Such amount is about 1 million reais above the fixed costs generated by 
itself, as identified in table 1. 
 
Table 7 – Appointments carried out in 2018 




January 76 98 174 
February 104 131 235 
March 86 130 216 
Total 266 359 625 
 
That is, operating under these circumstances, the unit has an expected forecast  
of 1,064 appointments for the industry and 1,436 academic appointments, totalling 
2,500 appointments, value way above the break-even point.  Thus, positioning itself 
as a surplus unit whose performance is positive. 
Nevertheless, the inventory of the implementation capacity of the unit is 300 
appointments a week.  That is, 15,600/year or 1,300/month. Keeping the proportion of 
the contribution of the implemented industry and academic protocols, the CTU could 
generate a contribution margin of R$ 16,483,584.00 a year (Table 8).  
 
Table 8 – Maximum expected contribution for the CTU 
Appointment capability Contribution Margin 
Industry Maximum Contribution Margin (6,640 appointments) R$ 8,786,048.00 /year 
Academic Maximum Contribution (8,960 appointments) R$ 7,697,536.00 /year 




With such information to hand, the unit manager traced expansion strategies to 
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 The results presented show that both protocols studied have contribution 
margin to cover similar fixed costs, composing about 80% of the revenues achieved 
by each one.  
 By the analysis of the break-even point, it is ascertained that the industry 
protocol has lower break-even point, presenting better performance than the academic 
one. Even with longer duration time, the result shows that the margin generated by the 
industry protocols are greater and ended up generating less need of year appointments 
so that the CTU reach positive results.   
In any case, it is important to highlight that this comparison assumes that all the 
other academic and industry protocols carried out by the CTU will have the same 
contribution margin and implementation time that those used in the research.  For a 
more consistent analysis, the managers should calculate an average contribution 
margin, statistically relevant, among different protocols.  
Assuming that the continuity assures that the result is the best way to indicate an 
organization’s performance11, even non-profit, this measurement way becomes a valid 
model for performance verification in the clinical trials unit studied.  
This layout ensures that the organization which does not have all its accounting 
data organized and structured can, based on a sample of few protocols, understand 
its performance and economic result.  It can be summarized by the following steps:  
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Picture 1. Steps to measure Performance via Break-even Point  
Source: created by the authors. 
 
 These steps evince the role of accounting in “providing economic, physical, 
productivity and social data relevant so that each user can make decisions and carry 
out their appropriate judgements safely”24.  
Since planning is the process of deciding which course of action should be taken 
for the future24, it can be seen that the result assessment in a non-profit activity is a 
useful treatment for the suitability of its future activities and resource control, bringing 
important information for planning  by the managers.  
Since a non-profit organization must revert benefits to the society, the 
administration and the bodies involved may judge the efficiency before applying 
resources in the entity.  In the study, it can be inferred that if the CTU operates with 
fewer active protocols than the break-even point, it would have low average 
performance. Nevertheless, since the operation has more protocols, the performance 
is considered positive.  
It is also worth highlighting that a complete analysis of the economic result 
should compare these profits, calculated with the break-even point, to the opportunity 
cost of the capital invested in the CTU.  Despite not being the aim of this study, its 
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importance in identifying whether the clinical trials unit is being feasible or another 
investment alternative would bring better return  is elucidated by this paragraph.  
 
CONCLUSION 
 With the measurement presented, the manager ascertained, within the 
limitations regarding the number of protocols used as basis, whether the number of 
protocols in the implementation stage - and the number of appointments - is in 
accordance with the break-even point presented.  
 This datum is extremely important, since problems regarding the origin of 
accounting information limit the complete survey on the composition of costs of trials 
units.  In fact, due to the limited information on costs, this CTU did not look into this 
information at all, incurring the “I think/ we think” and conflicting opinions among the 
agents involved in its management.  
 It can be said that this study pointed that the case selected measures the 
performance of the non-profit activity through its economic result, by means of the 
contribution margin and the use of break-even point.  This form can be replicated to 
other non-profit activities, ensuring more faithful information for the managers on the 
possibility of long-term continuity of the organization, premise of any organization11.  
Socially, this calculation brings the efficiency concept for the CTUs, referring to 
the benefits provided to the society, since their economic results evidence the ability 
of using scarce factors in order to generate products and services with higher 
economic value than the resources consumed, solving problems and meeting the 
needs which would not be met by isolated factors12, including the continuity of the 
generation of intangible benefits which were not the focus of this work.  
 It is necessary to reaffirm that the limitations present in the study point the need 
of subsequent researches.  It is recommended to:  
● Replicate the steps of the research to a multicase study with other clinical trials 
units; 
● Carry out research including not only tangible financial benefits and results, but 
also intangible benefits derived from the institution activities.   
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